Robert T. Schooley | Academic Influence

Robert T. Schooley's AcademicInfluence.com Rankings

Robert T. Schooley

Philosophy

#5513

World Rank

#8334

Historical Rank

Logic

#2778

World Rank

#3815

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert T. Schooley's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Robert T. Schooley Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert "Chip" T. Schooley is an American infectious disease physician, who is the Vice Chair of Academic Affairs, Senior Director of International Initiatives, and Co-Director at the Center for Innovative Phage Applications and Therapeutics , at the University of California San Diego School of Medicine. He is an expert in HIV and hepatitis C infection and treatment, and in 2016, was the first physician to treat a patient in the United States with intravenous bacteriophage therapy for a systemic bacterial infection.

(See a Problem?)

Robert T. Schooley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework (2001) (5642)
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 (1998) (3678)
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. (1987) (2759)
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. (2008) (2385)
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. (1997) (1316)
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. (2000) (1117)
Antiretroviral Treatment of Adult HIV Infection (2008) (1090)
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. (1985) (1023)
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. (1996) (1011)
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. (1998) (1006)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008) (828)
HIV-specific cytotoxic T lymphocytes in seropositive individuals (1987) (797)
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. (2002) (777)
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. (1986) (774)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. (2006) (769)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. (2004) (730)
Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus (2019) (672)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel (1996) (651)
Reducing transmission of SARS-CoV-2 (2020) (645)
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection (2017) (641)
Ten scientific reasons in support of airborne transmission of SARS-CoV-2 (2021) (497)
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). (1997) (493)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. (1996) (451)
HIV infection is blocked in vitro by recombinant soluble CD4 (1988) (420)
Panel on Clinical Practices for Treatment of HIV Infection (2000) (349)
HTLV-III in the semen and blood of a healthy homosexual man. (1984) (311)
Airborne transmission of SARS-CoV-2 (2020) (303)
RECOMBINANT HUMAN INTERFERON ALFA-A SUPPRESSES HTLV-III REPLICATION IN VITRO (1985) (292)
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study (2002) (288)
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins (1987) (287)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. (2004) (283)
Ribavirin antagonizes the effect of azidothymidine on HIV replication (1987) (281)
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. (1988) (264)
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. (1989) (250)
Subacute encephalomyelitis of AIDS and its relation to HTLV‐III infection (1987) (235)
SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2 (1992) (225)
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase (2013) (225)
ISOLATION OF HTLV-III/LAV FROM CERVICAL SECRETIONS OF WOMEN AT RISK FOR AIDS (1986) (224)
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon (1987) (217)
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California (2021) (215)
Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. (1981) (209)
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. (1989) (196)
Central-nervous-system lymphoma related to Epstein-Barr virus. (1983) (194)
Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex (1989) (193)
Infection of the retina by human immunodeficiency virus type I. (1987) (193)
Peripheral neuropathy in the acquired immunodeficiency syndrome (1988) (191)
CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine (1993) (185)
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. (1985) (184)
Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. (1983) (173)
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. (1985) (172)
Risk of Nosocomial Infection with Human T-Cell Lymphotropic Virus III (HTLV-III) (1985) (172)
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. (1990) (167)
Epstein-Barr virus superinduces a new human b cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts (1982) (164)
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. (2011) (164)
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF (2002) (155)
Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection (2018) (153)
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. (1986) (149)
Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. (1993) (145)
Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. (1983) (141)
Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage (2000) (141)
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. (2001) (140)
Whither or Wither Microbicides? (2008) (139)
Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. (1987) (130)
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States (2020) (130)
Antiretroviral therapies in women after single-dose nevirapine exposure. (2010) (130)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings (2012) (125)
Antiretroviral Therapy for Adult HIV-lnfected Patients: Recommendations From a State-of-the-Art Conference (1993) (121)
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients (2019) (121)
Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. (2019) (120)
Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion (2006) (118)
Report of the NIH Panel To Define Principles of Therapy of HIV Infection* (1998) (117)
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies (2018) (115)
Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient (2019) (115)
Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. (2010) (111)
Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. (1982) (107)
Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. (1979) (106)
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. (2010) (105)
Cytomegalovirus in the setting of infection with human immunodeficiency virus. (1990) (101)
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. (1981) (99)
HIV-specific cellular and humoral immune responses in primary HIV infection. (1996) (90)
Infrequency of isolation of HTLV-III virus from saliva in AIDS. (1985) (90)
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations (1981) (89)
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. (1989) (89)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. (1996) (87)
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV‐infected adults (1998) (85)
Detection of human anti‐HTLV‐III antibodies by indirect immunofluorescence using fixed cells (1985) (84)
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial (2019) (83)
Two‐dimensional Echocardiographic Assessment of the Idiopathic Hypereosinophilic Syndrome: Anatomic Basis of Mitral Regurgitation and Peripheral Embolization (1983) (82)
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group (1998) (80)
Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. (2012) (79)
Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. (1992) (78)
Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. (1983) (70)
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. (2009) (70)
Mononuclear cells in acute allograft glomerulopathy. (1987) (69)
Phage Therapy for Antibiotic-Resistant Bacterial Infections. (2021) (69)
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. (2012) (65)
The effect of infection on T lymphocyte subpopulations: a preliminary report. (1981) (64)
Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice. (2018) (61)
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. (1981) (59)
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon (1986) (57)
Radiosensitivity of HIV-1--potential application to sterilization of bone allografts. (1991) (55)
Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. (1989) (55)
Novel bacteriophage therapy for treatment of left ventricular assist device infection. (2019) (54)
Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral‐naive patients (1998) (54)
An adherence trilogy is essential for long-term HAART success. (2003) (54)
Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20) (2006) (54)
Antineutrophil antibodies in infectious mononucleosis. (1984) (53)
Nasal commensal Staphylococcus epidermidis counteracts influenza virus (2016) (53)
Ocular involvement associated with chronic Epstein-Barr virus disease. (1987) (53)
COVID-19—Lessons Learned and Questions Remaining (2020) (52)
Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. (1987) (52)
Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses (2013) (52)
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (1996) (52)
Antibody-dependent cell-mediated cytotoxicity against cells infected with the human immunodeficiency virus. (1987) (51)
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection (2015) (51)
Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer. (1985) (50)
The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. (1999) (50)
Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. (2010) (49)
Progressive increases in serum catalase activity in advancing human immunodeficiency virus infection. (1992) (49)
Real-Time In Vivo Green Fluorescent Protein Imaging of a Murine Leishmaniasis Model as a New Tool for Leishmania Vaccine and Drug Discovery (2008) (48)
Determination of receptor specificities for whole influenza viruses using multivalent glycan arrays. (2015) (46)
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. (2000) (46)
Rapid Multiplexed Immunoassay for Simultaneous Serodiagnosis of HIV-1 and Coinfections (2011) (45)
Resistance to antiviral drugs: the end of innocence. (1989) (45)
Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection (2012) (44)
Ophthalmoscopic and histologic findings in cytomegalovirus retinitis treated with BW-B759U. (1986) (44)
Effects of cycloheximide on the response of intestinal mucosa to cholera enterotoxin. (1973) (43)
The Octadecyloxyethyl Ester of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A Replicons (2009) (43)
Running with scissors: using antiretroviral therapy without monitoring viral load. (2008) (43)
Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease (2022) (42)
Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. (1988) (41)
Extensive Geographical Mixing of 2009 Human H1N1 Influenza A Virus in a Single University Community (2011) (40)
Possible viral interactions in the acquired immunodeficiency syndrome (AIDS). (1984) (39)
Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial (2012) (39)
Varicella-zoster virus envelope glycoproteins: biochemical characterization and identification in clinical material. (1985) (39)
Drug therapy. Treatment of herpesvirus infections. (1983) (39)
The Virome of Cerebrospinal Fluid: Viruses Where We Once Thought There Were None (2019) (38)
CD4+ human immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1-infected individual. (1993) (37)
Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. (2011) (37)
A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion. (1989) (37)
Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy (2008) (37)
Malignant lymphoma presenting as Kaposi's sarcoma in a homosexual man with the acquired immunodeficiency syndrome. (1985) (36)
Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome. (1988) (36)
Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop (2010) (36)
Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors (2008) (36)
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial (2012) (35)
Longer-term immunologic effects and side effects of successful antiretroviral therapy. (1999) (34)
Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. (2006) (33)
The essentiality of α‐2‐macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus (2010) (33)
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. (1995) (33)
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. (2014) (33)
Viral load testing in resource-limited settings. (2007) (32)
HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription. (1991) (32)
Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. (2000) (32)
Analysis of cellular immune response to EBV by using cloned T cell lines. (1983) (32)
Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study (2014) (32)
Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha (1984) (32)
Inactivation of Human Immunodeficiency Virus by Betadine (1987) (32)
Strengthening research capacity through the medical education partnership initiative: the Mozambique experience (2013) (31)
A multinational Delphi consensus to end the COVID-19 public health threat (2022) (31)
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. (2011) (31)
Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced infectious mononucleosis. (1979) (31)
Lymphocyte markers and infectious diseases. (1985) (31)
Cure of hemophilia A by orthotopic liver transplantation. (1988) (30)
Resolution of Cytomegalovirus Retinitis With Zidovudine Therapy (1988) (30)
Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets (2006) (30)
Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. (1998) (29)
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. (1999) (29)
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). (1985) (29)
Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs (2021) (28)
Development of suppressor T lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: assessment by two quantitative systems. (1981) (27)
In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. (1996) (27)
Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression. (2014) (27)
Safety , Tolerability , and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2 a in HIV-1 – Monoinfected Participants : A Phase II Clinical Trial (2010) (27)
Drug therapy. Treatment of herpesvirus infections. (1984) (26)
Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection (2021) (25)
Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy (2021) (25)
Need for an External Proficiency Testing Program for Cytokines, Chemokines, and Plasma Markers of Immune Activation (2000) (24)
Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty. (1977) (24)
A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia. (1990) (24)
Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: A Proof-of-Concept study. (2020) (24)
Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion. (2001) (24)
The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care (2015) (23)
Delineation of type-specific regions on the envelope glycoproteins of human T cell leukemia viruses. (1991) (23)
In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children. (1998) (23)
Detection of human T-cell lymphotropic virus type III-related antigens and anti-human T-cell lymphotropic virus type III antibodies by anticomplementary immunofluorescence (1986) (23)
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. (2019) (22)
A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy (2019) (20)
Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. (2013) (20)
Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child. (1993) (20)
Evaluation of SARS-CoV-2 transmission mitigation strategies on a university campus using an agent-based network model. (2021) (20)
P. falciparum Enhances HIV Replication in an Experimental Malaria Challenge System (2012) (20)
Modelling testing frequencies required for early detection of a SARS-CoV-2 outbreak on a university campus (2020) (20)
3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. (2008) (20)
The Medical Education Partnership Initiative (MEPI), a collaborative paradigm for institutional and human resources capacity building between high- and low- and middle-income countries: the Mozambique experience (2017) (19)
Antiretroviral chemotherapy. (1998) (19)
A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids (1988) (19)
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. (2014) (19)
Clinical Phage Microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy. (2021) (18)
Treat phage like living antibiotics (2020) (18)
A prospective observational study of bacteraemia in adults admitted to an urban Mozambican hospital. (2015) (17)
Factors indicative of outcome in a comparative trial of acyclovir and vidarabine for biopsy-proven herpes simplex encephalitis (2005) (16)
The Medical Education Partnership Initiative Effect on Increasing Health Professions Education and Research Capacity in Mozambique (2018) (16)
The Quest for an AIDS Vaccine (1988) (16)
Detection in 2009 of the Swine Origin Influenza A (H1N1) Virus by a Subtyping Microarray (2009) (16)
Flow cytometric screening for anti-leishmanials in a human macrophage cell line. (2010) (16)
Bacteriophage Treatment in a Lung Transplant Recipient (2018) (15)
Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) infection in men receiving treatment for HIV-1 infection. (1999) (15)
Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome (1990) (15)
Isolation of HTLV-III from CSF and neural tissues of patients with AIDS-related neurological syndromes (1987) (15)
Chronic fatigue syndrome: a manifestation of Epstein-Barr virus infection? (1988) (15)
Safe disinfection of contact lenses after contamination with HTLV-III. (1986) (15)
Status of immune‐based therapies in HIV infection and AIDS (1992) (14)
Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. (2000) (14)
Innovative Strategies for Transforming Internal Medicine Residency Training in Resource-Limited Settings: The Mozambique Experience (2014) (14)
Just (don't) do it. (1993) (14)
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. (2011) (14)
Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation. (1980) (14)
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
What’s Old Is New Again: Bacteriophage Therapy in the 21st Century (2019) (13)
No cure yet for HIV-1, but therapeutic research presses on. (2007) (13)
Facial erysipelas in the immunocompromised host. Report of two cases. (1981) (13)
Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs (2021) (13)
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. (2007) (13)
Th1/Th2 Cytokine Profile in Patients Coinfected with HIV and Leishmania in Brazil (2011) (13)
Circulating interferon gamma in AIDS patients treated with interleukin-2. (1988) (13)
Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis. (2014) (12)
Phage therapy: From biological mechanisms to future directions (2023) (12)
T-lymphocyte subset interactions in the cell-mediated immune response to Epstein-Barr virus. (1984) (12)
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant (2019) (12)
Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report (2015) (12)
Linked dual-class HIV resistance mutations are associated with treatment failure. (2019) (11)
Ocular Involvement Associated With Chronic Epstein-Barr Virus Disease (1987) (11)
Effect of interferon alpha on natural killer cell cytotoxicity in kidney transplant recipients. (1984) (11)
Immunophenotypic alterations in acute and early HIV infection. (2007) (11)
Interferon and natural killing of human lymphoma cell lines after induction of the Epstein Barr viral cycle by superinfection. (1984) (11)
A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa (2012) (10)
Effects of human immunodeficiency virus (HIV) on the cytotoxic response to Epstein Barr virus (EBV) transformed B lymphocytes. (1987) (10)
Pandemic (H1N1) 2009 Surveillance in Marginalized Populations, Tijuana, Mexico (2010) (10)
Erratum for Schooley et al., “Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection” (2018) (10)
Suppression of concanavalin A-induced blastogenesis by HTLV-III-infected H9 cells. (1986) (9)
Treatment of COVID-19 – Evidence-Based or Personalized Medicine? (2020) (9)
Phase 1 study of combination therapy with L-697,661 and zidovudine (1996) (9)
Predictors of Acute Liver Failure in Patients With Acute Hepatitis A: An Analysis of the 2016–2018 San Diego County Hepatitis A Outbreak (2019) (9)
Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping. (1992) (9)
Update on antiretroviral agents other than zidovudine (1989) (9)
Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor (2018) (8)
Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity. (2020) (8)
Animal Models of Phage Therapy (2021) (8)
Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India. (2013) (8)
Eosinophils as host cells for HIV-1 (2005) (8)
Why are Soft Skills Missing in Today's Applicants (2017) (8)
HIV and hepatitis C virus coinfection: bad bedfellows. (2005) (8)
Antiretroviral therapy as prevention: linking the mainframe to Main Street. (2011) (8)
Near patient CD4 count in a hospitalized HIV patient population (2017) (8)
Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe. (2014) (8)
The Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and Mozambique (2018) (8)
Comparative genomics of Acinetobacter baumannii and therapeutic bacteriophages from a patient undergoing phage therapy (2021) (7)
Antigen-presenting phagocytic cells ingest malaria parasites and increase HIV replication in a tumor necrosis factor α-dependent manner. (2014) (7)
Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial (2012) (7)
Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists. (2020) (7)
The human microbiome: implications for health and disease, including HIV infection. (2018) (7)
P084 Bacteriophage treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a cystic fibrosis patient (2018) (7)
Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. (2021) (6)
A longitudinal systems immunologic investigation of acute Zika virus infection in an individual infected while traveling to Caracas, Venezuela (2018) (6)
Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524) (2021) (6)
Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. (2021) (6)
Two-dimensional Echocardiographic Assessment of the Idiopathic Hypereosinophilic Syndrome (2005) (6)
A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience (2000) (6)
Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. (2004) (6)
Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) (2021) (6)
Dot immunobinding assay for detection of human immunodeficiency virus-associated antigens (1987) (6)
Safety and Efficacy of Bacteriophage Therapy in Lung Transplant Candidates and Recipients (2019) (6)
Skating to Where the Puck Is Going to Be. (2017) (6)
A Plea for Justice for Jailed Medical Workers (2006) (5)
Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations. (2012) (5)
Pandemic (H1N1) 2009 Surveillance in Marginalized Populations (2010) (5)
High affinity CXCR4 inhibitors generated by linking low affinity peptides. (2019) (5)
Epstein—Barr virus (1989) (5)
Strategies and progress in CXCR4-targeted anti-HIV therapeutic development. (2021) (5)
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus (2019) (5)
A flow cytometric technique for quantitation of B-cell activation. (1984) (5)
HIV antibody screening in a low‐risk population (blood donors) (1987) (5)
Discovery and Computational Analyses of Novel Small Molecule Zika Virus Inhibitors (2019) (5)
The fragile relationship between hepatitis C virus and its human host. (2014) (5)
Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi’s Sarcoma-Associated Herpesvirus (2016) (5)
Biomedical research capacity building in Mozambique through the MEPI (2014) (4)
p16 Expression Correlates with Invasive Ocular Surface Squamous Neoplasms in HIV-Infected Mozambicans (2019) (4)
Our Warming Planet: Is the HIV-1-Infected Population in the Crosshairs. (2016) (4)
Treatment of herpesvirus infectious (second of two parts) (1983) (4)
Design and Implementation of Postgraduate Programs in Health in a Resource-Limited Setting in Mozambique (The Lúrio University) (2021) (4)
Psychiatric disease and cytomegalovirus viremia in renal transplant recipients. (1995) (4)
Herd Immunity Likely Protected the Men Who Have Sex With Men in the Recent Hepatitis A Outbreak in San Diego, California (2018) (4)
Stimulation of Kaposi's sarcoma‐associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim (2004) (3)
Low-cost, multiplexed biosensor for disease diagnosis (2009) (3)
Controlling the HIV epidemic, without a vaccine! (2008) (3)
Immunomodulatory effects of antiretroviral chemotherapy. (1995) (3)
Development of host immune response to bacteriophage in a lung transplant recipient on adjunctive phage therapy for a multidrug resistant pneumonia. (2022) (3)
A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, (2012) (3)
3 – Host Responses to Infection (2017) (3)
Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. (1996) (3)
Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4 (2019) (3)
HIV‐1 Infection Does Not Induce Tumor Necrosis Factor‐α or Interferon‐β Gene Transcription (1991) (3)
Resolution of cytomegalovirus retinitis with zidovudine therapy. Case report. (1988) (3)
Antiretroviral and immune-based therapies: update. (1993) (3)
15Anti-Hepatitis C Virus Replicon Activity of Alkoxyalkyl Esters of (S)-HPMPA and Other Acyclic Nucleoside Phosphonates (2008) (3)
1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data (2018) (3)
Hepatitis C virus therapeutics: at the end of the beginning. (2012) (2)
Successful Bacteriophage Therapy for Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infection in a Cystic Fibrosis Patient (2019) (2)
Challenges in the clinical development of antiretroviral drugs. (1992) (2)
Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate. (2019) (2)
Monitoring of Delay to Pharmacy Refill in Assessing Adherence to Antiretroviral Therapy (2018) (2)
The Impact of Direct Acting Antivirals in the Cure of HCV in HIV-Infected Patients with Ongoing Barriers to Care (2015) (2)
The Role of Interferons in Viral Infections in Immune Compromised Patients (1984) (2)
Expression of concern relating to Naucler et al. (2019) (2)
Therapy of human immunodeficiency virus infections. (1987) (2)
Antimicrobial Resistance - The Glass Is Half Full. (2020) (2)
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique. (2018) (2)
Fostering Sustainable Biomedical Research Training in Mozambique: A Spin-Off of the Medical Education Partnership Initiative (2022) (2)
Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology (2012) (2)
The essentiality of α‐2‐macroglobulin in human salivary innate immunity against new H1N1 swine origin influenza A virus (2010) (2)
Herd Immunity Likely Protected the Men who have Sex with Men in Recent Hepatitis A Outbreak in San Diego CA. (2018) (1)
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial (2022) (1)
Immunological monitoring of diabetic and nondiabetic recipients of renal allografts. (1983) (1)
HIV-1-specific cytotoxic T-cell responses. (1995) (1)
Synthesis and Antiviral Activity of 3-Methoxy-2-(phosphonomethoxy)propyl Nucleoside Esters Against HCV and HIV-1 (2011) (1)
PT247 Anemia is a Predictor of Cardiac Abnormalities and Systolic Function Worsening in a African Population With Access to Antiretroviral Therapy (2016) (1)
Managing HIV. Part 4: Primary therapy. 4.2 Immune-based therapy for HIV infection. (1996) (1)
Effects on the microbiome during treatment of a staphylococcal device infection (2021) (1)
Book ReviewThe AIDS Challenge: Prevention education for young people Understanding and Preventing AIDS: A book for everyone (1989) (1)
Monoclonal Antibody Against Ebv-Associated Transformation Antigen Detected in vitro and in vivo (1982) (1)
Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase (2013) (1)
Check, but not checkmate. (1997) (1)
INTERFERON IN RENAL TRANSPLANT RECIPIENTS (1982) (1)
A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist. (2022) (1)
707 Anti-viral activities of preferentialy propagated CD4+ and CD8+ T cell subsets from hiv-infected subjects (1991) (1)
Profile of bacterial infectious disease and antimicrobial choices in an urban hospital at Maputo, Mozambique: a prospective observational study (2019) (1)
Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War? (2015) (1)
Enhanced Cellular Penetration of ODE-(S)-MPMPA Accounts for Its Prolonged Post-exposure Anti-HCV Activity (2011) (1)
470 CHANGES IN INTERFERON-GAMMA INDUCIBLE PROTEIN-10 IN TREATMENT-NAÏVE VERSUS TREATMENT-EXPERIENCED PATIENTS GIVEN AN ALL-ORAL ANTI-HCV REGIMEN (2013) (1)
Isolation of a Peptide That Binds to Pseudomonas aeruginosa Lytic Bacteriophage (2022) (1)
Antibodies to EBV Specific Enzymes in the Chronic EBV Syndrome (1987) (1)
HPV16/18 and p16 gene expression in ocular surface squamous neoplasia: a retrospective cross-sectional analysis (2018) (1)
4.2 Immune‐based therapy for HIV infection (1996) (0)
Facial Erysipelas in the Immunocompromised Host (2017) (0)
HIV Therapeutics, 2005: New Drugs, New Approaches (2004) (0)
Exploring bacteriophage therapy for drug-resistant bacterial infections. (2023) (0)
The Serendipity of Life, Medicine, and Science (2001) (0)
SEROPREVALENCE OF HHV-8 IN PATIENTS WITH AND At RISK FOR KAPOSI'S SARCOMA IN THE US AND BRAZIL: 25 (1997) (0)
1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity (2023) (0)
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial (2022) (0)
Improving Adherence to Complex Medical Regimens through the Integration of Knowledge , Technology and Informatics (2012) (0)
Report on the therapeutic vaccine workshop: National Cooperative Vaccine Development group meeting (1993) (0)
PERSPECTIVES FOR LYMPHOKINE THERAPY: FROM GENETIC ENGINEERING TO IMMUNOLOGIC ENGINEERING* (1987) (0)
Reply to Christopher and Kortepeter. (2015) (0)
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297) (2021) (0)
A systematic review and meta-analysis of the epidemiology of Leptospirosis in HIV uninfected and in people living with HIV from the Southern African Development Community (2022) (0)
Morbidity in Compromised Patients Related to Viruses Other Than Herpes Group and Hepatitis Viruses (1988) (0)
Structure -based discovery of potential small-molecule inhibitors targeting Zika virus NS3 helicase (2017) (0)
Closing the Gaps on Medical Education in Low-Income Countries Through Information & Communication Technologies: The Mozambique Experience (2019) (0)
[Chemotherapy and immunoprophylaxis of HIV infection]. (1986) (0)
Therapeutic perspectives in human immunodeficiency virus infection. (1987) (0)
Title Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection : Implications for the innate immune response Permalink (2014) (0)
Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. (1996) (0)
A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa (2012) (0)
syndrome. II. Clinical manifestations A clinicopathologic correlation of the idiopathic hypereosinophilic (2011) (0)
Twenty-Fourth International Conference on Antiviral Research - Front Pages (2011) (0)
HPV 16 / 18 and p 16 Gene Expression in Ocular Surface Squamous Neoplasia : a Retrospective Analysis of 49 cases from Zimbabwe , Africa (2021) (0)
Research-Based Careers (2017) (0)
HIV post-treatment controllers have distinct immunological and virological features. (2023) (0)
EPIDEMIOLOGIC STUDIES OF HUMAN HERPES VIRUS-8 IN ZIMBABWE. (1998) (0)
of falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population. (2015) (0)
Chapter 2 – Host responses to infection (2010) (0)
Information , Inspiration and Advocacy for People Living with HIV / AIDS (2004) (0)
The Association Between Ocular Surface Squamous Neoplasia and Human Papilloma Virus in HIV Sero-positive Mozambicans (2017) (0)
Introduction to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Supplement (2021) (0)
Diversified repertoire of phage defenses in Klebsiella pneumoniae: Bi-directional steering effects impacting antibiotic susceptibility (2022) (0)
Contributors (2012) (0)
Titer affinity parameter a new blood marker for monitoring individuals with hiv disease (1990) (0)
Reply to Meyerowitz and Richterman. (2021) (0)
Susceptibility antibiotic screening reveals high rates of multidrug resistance of Salmonella, Shigella and Campylobacter in HIV infected and uninfected patients from Mozambique (2023) (0)
TH1/TH2 CYTOKINE PROFILE IN HIV AND LEISHMANIA CO-INFECTED PATIENTS (2011) (0)
Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir (2022) (0)
Therapeutic decision making in 1997. Roundtable discussion of five cases. (1997) (0)
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant <named-content content-type='genus-species'>Acinetobacter baumannii</named-content> Infection (2017) (0)
Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population (2015) (0)
Genetically Engineered Phage Therapy 'Saves' Teen From Drug-Resistant Infection (2020) (0)
IV-1 gp120-CXCR4 recognition probed with synthetic nanomolar affinity D-peptides containing fragments of gp120 V3 loop. (2022) (0)
Assessment of the microbiome during bacteriophage therapy in combination with systemic antibiotics to treat a case of staphylococcal device infection (2021) (0)
Cancer, more than a “COVID-19 co-morbidity” (2023) (0)
An AIDS Body — Living with Lipodystrophy (2002) (0)
Title A cross-sectional study of subclinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique , South-Eastern Africa Permalink (2012) (0)
821 ODE-(S)-MPMPA DISPLAYS POTENT HCV REPLICÓN SUPPRESSION FOR ONE WEEK AFTER COMPOUND REMOVAL IN CELL CULTURE (2011) (0)
CD4 Counts as Surrogate Markers for Progression to AIDS (1994) (0)
Clinical Approach to Infection in the Compromised Host (1988) (0)
We Didn't Start the Fire. (2022) (0)
domains on the envelope glycoproteins. antibodies recognize several conserved Human immunodeficiency virus neutralizing (2013) (0)
Lines from HIV-1-Infected Children In Vitro Effects of IL-12 on HIV-1-Specific CTL (2017) (0)
From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic Resistant Infections (2018) (0)
Rong’s Numbers: Accelerating Progress in HCV Therapeutic Research (2010) (0)
Human H1N1 Influenza A Virus in a Single Extensive Geographical Mixing of 2009 (2011) (0)
Pathogenesis and Clinical Manifestations of HIV-1 Infection (2002) (0)
Reply to Messori et al. (2013) (0)
Waltzing HIV-tilda. (1988) (0)
Structural and Biological Characterizations of Novel High-A ffi nity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR 4 (2019) (0)
Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response (2014) (0)
Starting Highly Active Antiretroviral Therapy for HIV Infection: Is It WIHS To Wait? (2004) (0)
Factors Associated with Pulmonary Involvement and Mortality in Kaposi Sarcoma at Maputo Central Hospital (2019) (0)
Status ofimmune-based therapies inHIVinfection andAIDS (1992) (0)
A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. (2017) (0)
Clinical Care Conundrums: HIV Patient Care in 2016: A Case-Based, Panel Discussion (2016) (0)
Alternative Language Abstract S2 (2012) (0)
IAS-USA Board of Directors (2011) (0)
Topics in HIV Medicine ® Perspectives HIV and Hepatitis C Virus Coinfection : Bad Bedfellows 112 (2005) (0)
Book ReviewVirology in Medicine (1986) (0)
Chronic Epstein-Barr virus infection tired terminology for an unrelated phenomenon (1988) (0)
Book ReviewMicrobiology in Clinical Practice (1990) (0)
Novel bacteriophage therapy for BT was administered without adverse clinical or labora-treatment of left ventricular assist device infection (2019) (0)
Clinical Phage Microbiology: A suggested in-vitro framework for phage therapy (2021) (0)
Molecular Mirror Technology Facilitates High-Throughput, Accurate SARS-CoV-2 Testing (2021) (0)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-1986. An asplenic woman with evidence of sepsis and diffuse intravascular coagulation after a dog bite. (1986) (0)
Coinfection of HIV-1 with Schistosoma spp. and with Intestinal Parasites in Patients Attending Boane Health Center, Maputo Province, Mozambique. (2021) (0)
Intestinal Mucosa to Cholera Enterotoxin (1973) (0)
385 – Epstein-Barr Virus Infection (2012) (0)
Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--end points. (1990) (0)

This paper list is powered by the following services:

Other Resources About Robert T. Schooley

en.wikipedia.org

What Schools Are Affiliated With Robert T. Schooley?

Robert T. Schooley is affiliated with the following schools:

Image Attributions

Image Source for Robert T. Schooley